Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency disease characterized by eczema, recurrent staphylococcal aureus skin abscesses, pneumonia with pneumatocele formation, remarkably high serum IgE levels, eosinophilia and involvement of skeleton and connective tissues. Heterozygous signal transducer and activator of transcription 3 (STAT3) mutations were shown to be the cause of autosomal dominant HIES (AD-HIES). In this study, we diagnosed nine patients with HIES from 9 unrelated families on the basis of a National Institutes of Health (NIH) score of ≥40 points, sequenced the STAT3 gene of all nine patients, and quantified Th17 cells in peripheral blood of seven patients by flow cytometry in mainland China. All nine patients had characteristic manifestation of HIES with the range of NIH scores 45-77 points. STAT3 hot mutations V637M or R382W/Q were identified in five patients. We identified two novel heterozygous missense mutations (T620S and R609G) located in Src homology 2 (SH2) domain in two patients, respectively. In two other patients, no STAT3 mutations were found. Quantified Th17 cell numbers were markedly decreased or absent (0-0.28% of CD4 + T cells) in six patients with STAT3 mutations and almost normal (0.53% of CD4 + T cells) in one wild-type STAT3 patient compared with healthy controls (0.40-2.25% of CD4 + T cells). These results suggest that not all patients with HIES who had NIH scores over 40 points carry STAT3 mutations, those whose Th17 cell numbers strikingly decreased probably had AD-HIES with STAT3 mutations.
Our research aimed to look into the clinical traits and genetic mutations in sporadic
non-syndromic anodontia and to gain insight into the role of mutations of
PAX9, MSX1, AXIN2 and EDA in anodontia
phenotypes, especially for the PAX9.Material and Methods:The female proband and her family members from the ethnic Han families underwent
complete oral examinations and received a retrospective review. Venous blood
samples were obtained to screen variants in the PAX9, MSX1,
AXIN2, and EDA genes. A case-control study was performed
on 50 subjects with sporadic tooth agenesis (cases) and 100 healthy controls,
which genotyped a PAX9 gene polymorphism (rs4904210). Results:Intra-oral and panoramic radiographs revealed that the female proband had
anodontia denoted by the complete absence of teeth in both the primary and
secondary dentitions, while all her family members maintained normal dentitions.
Detected in the female proband were variants of the PAX9 and
AXIN2 including A240P (rs4904210) of the
PAX9, c.148C>T (rs2240308), c.1365A>G (rs9915936) and
c.1386C>T (rs1133683) of the AXIN2. The same variants were
present in her unaffected younger brother. The PAX9 variations
were in a different state in her parents. Mutations in the MSX1
and EDA genes were not identified. No significant diferences were
found in the allele and genotype frequencies of the PAX9
polymorphism between the controls and the subjects with sporadic tooth agenesis.
Conclusions:These results suggest that the association of A240P with
sporadic tooth agenesis still remains obscure, especially for different
populations. The genotype/phenotype correlation in congenital anodontia should be
verified.
Peroxisome proliferator-activated receptor γ (PPARγ) is a versatile member of the ligand-activated nuclear hormone receptor superfamily of transcription factors, with expression in several different cell lines, especially in the digestive system. After being activated by its ligand, PPARγ can suppress the growth of oral, esophageal, gastric, colorectal, liver, biliary, and pancreatic tumor cells, suggesting that PPARγ ligand is a potential anticancer agent in PPARγ-expressing tumors. This review highlights key advances in understanding the effects of PPARγ ligands in the treatment of tumors in the digestive system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.